Neocarbo (Carboplatin)

Carboplatin, the active ingredient in Neocarbo, is a platinum compound presented as an injectable solution for intravenous use. It is employed in the treatment of various solid tumours, including ovarian, non‑small cell lung and head‑and‑neck cancers, in adult patients.

GNH USA supplies Neocarbo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Carboplatin is a platinum‑based chemotherapeutic used primarily for solid tumour management. - Ovarian cancer: improves response rates when combined with surgery or other chemotherapy agents. - Non‑small cell lung cancer: used as first‑line or second‑line therapy, often with paclitaxel. - Head and neck cancer: administered in concurrent chemoradiation protocols to enhance tumour control. - Bladder cancer: employed in combination regimens for advanced or metastatic disease.

Carboplatin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Myelosuppression: reduced white blood cells, platelets, and red cells. - Fatigue: generalized tiredness during treatment cycles. - Electrolyte disturbances: especially low magnesium. - Mild renal function changes: transient increase in serum creatinine.

Serious or Rare Side Effects: - Severe neutropenia or thrombocytopenia leading to infection or bleeding. - Anaphylactic reactions: rare but potentially life‑threatening hypersensitivity. - Ototoxicity: hearing loss, particularly at high cumulative doses. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Secondary malignancies: rare risk of therapy‑related leukemia.

When using Carboplatin, clinicians should observe several safety measures. - Renal function monitoring: assess serum creatinine and adjust dose as needed. - Hematologic surveillance: perform regular complete blood counts to detect myelosuppression. - Hydration status: ensure adequate intravenous fluids to protect kidney function. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or infant risks. - Drug interactions: review concomitant medications for additive myelosuppressive effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Carboplatin can interact with other agents, influencing efficacy or toxicity.

Major Interactions (Avoid): - Nephrotoxic drugs (e.g., cisplatin, aminoglycosides): may exacerbate renal impairment. - Myelosuppressive agents (e.g., high‑dose methotrexate): increase risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Loop diuretics: may affect electrolyte balance and renal clearance. - Anticoagulants (e.g., warfarin): monitor coagulation parameters due to potential platelet count changes. - Radiotherapy: combined use can heighten tissue toxicity; schedule coordination is advised.